Liquidia Technologies, Inc. (LQDA): Price and Financial Metrics

Liquidia Technologies, Inc. (LQDA): $14.75

0.32 (-2.12%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

C

LQDA Price/Volume Stats

Current price $14.75 52-week high $16.99
Prev. close $15.07 52-week low $5.71
Day low $14.63 Volume 2,048,800
Day high $15.12 Avg. volume 987,748
50-day MA $14.22 Dividend yield N/A
200-day MA $9.35 Market Cap 1.12B

LQDA Stock Price Chart Interactive Chart >

LQDA POWR Grades

  • LQDA scores best on the Sentiment dimension, with a Sentiment rank ahead of 59.89% of US stocks.
  • The strongest trend for LQDA is in Quality, which has been heading down over the past 26 weeks.
  • LQDA's current lowest rank is in the Growth metric (where it is better than 6.87% of US stocks).

LQDA Stock Summary

  • With a price/sales ratio of 40.22, LIQUIDIA CORP has a higher such ratio than 96.16% of stocks in our set.
  • With a year-over-year growth in debt of 97.09%, LIQUIDIA CORP's debt growth rate surpasses 91.66% of about US stocks.
  • Revenue growth over the past 12 months for LIQUIDIA CORP comes in at 32.83%, a number that bests 85.85% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to LIQUIDIA CORP, a group of peers worth examining would be ASTC, FCEL, ROIV, AKTS, and NWBO.
  • Visit LQDA's SEC page to see the company's official filings. To visit the company's web site, go to www.liquidia.com.

LQDA Valuation Summary

  • In comparison to the median Healthcare stock, LQDA's EV/EBIT ratio is 197.95% lower, now standing at -14.3.
  • LQDA's EV/EBIT ratio has moved down 2.7 over the prior 66 months.

Below are key valuation metrics over time for LQDA.

Stock Date P/S P/B P/E EV/EBIT
LQDA 2023-12-29 42.6 16.3 -13.6 -14.3
LQDA 2023-12-28 42.8 16.3 -13.6 -14.4
LQDA 2023-12-27 43.2 16.5 -13.7 -14.5
LQDA 2023-12-26 41.2 15.7 -13.1 -13.8
LQDA 2023-12-22 41.7 15.9 -13.3 -14.0
LQDA 2023-12-21 39.9 15.2 -12.7 -13.4

LQDA's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • LQDA has a Quality Grade of D, ranking ahead of 6.72% of graded US stocks.
  • LQDA's asset turnover comes in at 0.106 -- ranking 153rd of 186 Medical Equipment stocks.
  • 500 - Internal server error

The table below shows LQDA's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.106 0.756 -1.103
2021-06-30 0.075 0.771 -1.558
2021-03-31 0.049 0.756 -2.131
2020-12-31 0.011 0.679 -2.776
2020-09-30 0.000 NA -3.022
2020-06-30 0.000 NA -2.692

LQDA Price Target

For more insight on analysts targets of LQDA, see our LQDA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $4.25 Average Broker Recommendation 1.5 (Moderate Buy)

Liquidia Technologies, Inc. (LQDA) Company Bio


Liquidia Technologies, Inc., a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of human therapeutics. Its lead product candidate, LIQ861, an inhaled dry powder formulation of treprostinil that is in Phase III clinical trials used for the treatment of pulmonary arterial hypertension. The company is also developing LIQ865, which completed Phase Ib clinical trials for the treatment of local post-operative pain. The company was founded in 2004 and is based in Morrisville, North Carolina.


LQDA Latest News Stream


Event/Time News Detail
Loading, please wait...

LQDA Latest Social Stream


Loading social stream, please wait...

View Full LQDA Social Stream

Latest LQDA News From Around the Web

Below are the latest news stories about LIQUIDIA CORP that investors may wish to consider to help them evaluate LQDA as an investment opportunity.

Biotech CEOs Are Buying Up Their Surging Stocks

Shares of Cibus, OmniAb, and Liquidia—three small biotechs—have seen big gains this year. Their CEOs just bought more stock.

Yahoo | December 25, 2023

Peabody Energy, Janus International, and More Stocks See Action From Activist Investors

Activists file with the SEC on Liquidia, Janus International Group, Peabody Energy, Disc Medicine, and Blue Bird.

Yahoo | December 22, 2023

Industry Analysts Just Upgraded Their Liquidia Corporation (NASDAQ:LQDA) Revenue Forecasts By 38%

Liquidia Corporation ( NASDAQ:LQDA ) shareholders will have a reason to smile today, with the analysts making...

Yahoo | December 22, 2023

Independent Director of Liquidia Picks Up 5.3% More Stock

Those following along with Liquidia Corporation ( NASDAQ:LQDA ) will no doubt be intrigued by the recent purchase of...

Yahoo | December 21, 2023

U.S. Federal Circuit Affirms Earlier PTAB Decision to Invalidate All Claims of United Therapeutics Patent No. 10,716,793 (‘793 Patent)

Liquidia will pursue final FDA approval for YUTREPIA™ (treprostinil) inhalationLiquidia will immediately request that District Court set aside injunction tied to ‘793 patent MORRISVILLE, N.C., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) announced that the U.S. Court of Appeals for the Federal Circuit (Federal Circuit) today affirmed the earlier decision by the Patent Trial and Appeal Board (PTAB) which found all claims of U.S. Patent No. 10,716

Yahoo | December 20, 2023

Read More 'LQDA' Stories Here

LQDA Price Returns

1-mo 2.54%
3-mo 22.61%
6-mo 132.65%
1-year 118.84%
3-year 480.71%
5-year 29.61%
YTD 22.61%
2023 88.85%
2022 30.80%
2021 65.08%
2020 -30.99%
2019 -80.26%

Continue Researching LQDA

Want to see what other sources are saying about Liquidia Technologies Inc's financials and stock price? Try the links below:

Liquidia Technologies Inc (LQDA) Stock Price | Nasdaq
Liquidia Technologies Inc (LQDA) Stock Quote, History and News - Yahoo Finance
Liquidia Technologies Inc (LQDA) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!